JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Jong, M.
Right arrow Articles by Krenning, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Jong, M.
Right arrow Articles by Krenning, E. P.

Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs

Marion de Jong, PhD;, Wout A.P. Breeman, PhD;, Roelf Valkema, MD;, Bert F. Bernard and Eric P. Krenning, MD

Department of Nuclear Medicine, Erasmus Medical College, Rotterdam, The Netherlands



View larger version (15K):

[in a new window]
  		FIGURE 1. Structures of the somatostatin analogs Tyr3-octreotide and Tyr3-octreotate and of the chelator DOTA.

 


View larger version (27K):

[in a new window]
  		FIGURE 2. (A) Survival curves of groups of rats (n = 8–15), each bearing both a small (approximately 0.5 cm2) and a large (7–9 cm2) somatostatin receptor-positive rat pancreatic CA20948 tumor in the flanks. Rats were treated with single intravenous administrations of 370 MBq 90Y-DOTATOC (indicated as 90Y), 370 MBq 90Y-DOTA, 555 MBq 177Lu-DOTATATE (indicated as 177Lu), or 185 MBq 90Y-DOTATOC plus 278 MBq 177Lu-DOTATATE (indicated as 177Lu + 90Y). Control rats did not receive radioactivity. (B) Bars indicate the criteria for euthanasia. Rats were sacrificed when size of large tumors, small tumors, or both tumors exceeded 15 cm2. When neither tumor grew, animals were sacrificed at day 150 after therapy.

 


View larger version (25K):

[in a new window]
  		FIGURE 3. (A) Survival curves of groups of rats (n = 8–15), each bearing both a small (approximately 0.5 cm2) and a large (7–9 cm2) somatostatin receptor-positive rat pancreatic CA20948 tumor in the flanks. Rats were treated with 2 intravenous administrations (2 wk apart) of 2 x 111 MBq 90Y-DOTATOC (indicated as 90Y), 2 x 278 MBq 177Lu-DOTATATE (indicated as 177Lu), or 2 x 56 MBq 90Y-DOTATOC plus 2 x 140 MBq 177Lu-DOTATATE (indicated as 177Lu + 90Y). Control rats did not receive radioactivity. (B) Bars indicate the criteria for euthanasia. Rats were sacrificed when size of large tumors, small tumors, or both tumors exceeded 15 cm2. When neither tumor grew, animals were sacrificed at day 150 after therapy.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.